feedback

Course Director

George D. Demetri, MD
George D. Demetri, MD

Dana-Farber Cancer Institute
Ludwig Center at Harvard
Harvard Medical School
Boston, Massachusetts

Faculty

Alexander Drilon
Alexander Drilon, MD

Memorial Sloan Kettering Cancer Center
New York, New York

Anna F. Farago
Anna F. Farago, MD, PhD

Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2018-Jul-09
Expiration Date:2019-Jul-08
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this CME activity, which is based on a live symposium held at the 2018 annual clinical oncology meeting in Chicago, oncology experts take you behind the science that has led to the emergence of tropomyosin receptor kinase (TRK) fusions as a tumor-agnostic therapeutic target, and guide you through the evidence to date on TRK fusion inhibitors. Important topics to be discussed include the use of appropriate biomarker tests to confirm the presence of TRK fusions, how to select patients for treatment, potential therapeutic applications of TRK inhibitors based on the early evidence, and overcoming resistance to therapy. In addition, this activity features a look at the future via a profile of ongoing studies testing TRK fusion inhibitors in several adult and pediatric patient populations.

Upon completion of this activity, participants should be better able to:
  • Describe the biology of and rationale for targeting TRK fusions in the cancer setting
  • Summarize efficacy and safety evidence on the use of TRK fusion inhibitors in a range of cancers harboring NTRK fusion proteins, including breast, lung, GI, and CNS cancers, among others
  • Recommend strategies for confirming the presence of TRK fusions in cancer based on an understanding of the role of established and emerging biomarker assays
  • Identify adult and pediatric patients with cancer who may be candidates for enrollment in clinical trials testing TRK fusion inhibitors

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, and other healthcare professionals involved in the care of patients with cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 09, 2018 - July 08, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

George D. Demetri, MD
Senior Vice President for Experimental Therapeutics
Dana-Farber Cancer Institute
Co-Director, Ludwig Center at Harvard
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

George D. Demetri, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer Corporation; Bessor Pharma LLC; Blueprint Medicines; Caris Life Sciences; Champions Oncology; Daiichi Sankyo, Inc.; Eli Lilly and Company; EMD Serono, Inc.; Epizyme; G1 Therapeutics; Ignyta; Janssen Oncology; LOXO Oncology; Merrimack Pharmaceuticals; Mirati Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer Inc.; PharmaMar; Polaris Pharmaceuticals, Inc.; Sanofi-Aventis U.S. LLC. (Oncology); WIRB Copernicus Group; and ZIOPHARM Oncology, Inc.
Grant/Research Support from AbbVie Inc.; Adaptimmune; Bayer Corporation; Epizyme; Ignyta; Janssen Oncology Global Services, LLC (Oncology); LOXO Oncology; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Equity in Bessor Pharma LLC; Blueprint Medicines, Caris Life Sciences Inc.; Champions Oncology; G1 Therapeutics; and Merrimack Pharmaceuticals. Blueprint Medicines and Merrimack Pharmaceuticals where Dr. George Demetri serves as a Member of the Board of Directors.

George D. Demetri, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: larotrectinib, entrectinib, LOXO-195, ropotrectinib, and other investigational TRK fusion inhibitors with tumor-agnostic activity.

Faculty

Alexander Drilon, MD
Clinical Director, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Medicines; F. Hoffmann-La Roche/Genentech, Inc.; Helsinn Therapeutics (US) Inc.; Ignyta; LOXO Oncology; Pfizer, Inc.; Takeda Pharmaceutical Company Limited and TP Therapeutics, Inc.

Alexander Drilon, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: larotrectinib, entrectinib, LOXO-195, ropotrectinib, and other investigational TRK fusion inhibitors with tumor-agnostic activity.

Anna F. Farago, MD, PhD
Assistant in Medicine
Massachusetts General Hospital
Instructor in Medicine
Harvard Medical School
Boston, Massachusetts

Anna F. Farago, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AbbVie Inc.; AbbVie/Stemcentrx; AstraZeneca; Bristol-Myers Squibb; Ignyta; LOXO Oncology; Merck & Company, Inc.; Novartis Pharmaceuticals Corporation; and PharmaMar. Research funding goes to Institution.
Honorarium from Foundation Medicine.
Consultant and/or Advisor for AbbVie; AbbVie/Stemcentrx; Loxo Oncology; PharmaMar; and Takeda.

Anna F. Farago, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: larotrectinib, entrectinib, LOXO-195, ropotrectinib, and other investigational TRK fusion inhibitors with tumor-agnostic activity.

CME Reviewer

Siyang Leng, MD

Siyang Leng, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Bayer US and LOXO Oncology, and Genentech.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.